UROGEN PHARMA LTD

URGN is the Nasdaq ticker symbol for UroGen Pharma Ltd., a commercial-stage biopharmaceutical company. The stock represents an ownership stake in the company, which focuses on developing and commercializing treatments for urothelial and bladder cancers. URGN trades on the Nasdaq Global Market under that symbol.

URGN's current stock price changes throughout each trading session. The latest live price, along with the day's change and percentage move, is displayed on this page. For the most accurate and up-to-date quote, refer to the real-time data shown above rather than relying on any fixed figure.

URGN has historically shown meaningful price volatility, which is common for small-cap biopharmaceutical companies. Its share price can move sharply around clinical trial updates, regulatory news, and quarterly earnings. Historical volatility measures, such as beta or the 52-week price range, can help investors gauge how widely URGN shares have traded over time.

Evaluating URGN's valuation often involves more than standard earnings multiples, since many biopharma companies reinvest heavily in research and development. Investors may consider price-to-sales, price-to-book, cash position, pipeline potential, and comparable company analysis. Because URGN's financial profile is specific to the biotechnology sector, reviewing its latest reported figures and the valuation metrics displayed on this page is important.

Analyzing URGN's financial performance involves reviewing its quarterly and annual reports, including the income statement, balance sheet, and cash flow statement. Revenue trends for its commercial products, research and development spending, operating expenses, and cash burn are key items. Earnings releases and SEC filings provide the most reliable data for tracking URGN's financial progress over time.

Key risks for URGN include clinical trial failures, regulatory delays or rejections, and the challenge of commercializing treatments in competitive markets. As a smaller biopharmaceutical company, URGN may also face financing needs, reliance on a limited product portfolio, and potential share dilution. Broader sector sentiment and changes in healthcare reimbursement can further affect the stock.